Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.

Journal of neuro-oncology - 7 May 2026

Andrade Anais, Mureb Monica, Karaman Nilay, Liu Cindy, Sabari Joshua K, Veluswamy Rajwanth R, Bernstein Kenneth, Donahue Bernadine R, Cooper Benjamin T, Kondziolka Douglas

Abstract excerpt

PURPOSE: KRAS G12C mutations occur in approximately 11% of non-small-cell lung cancer (NSCLC) patients and are associated with aggressive disease and poor prognosis. Although KRAS G12C-inhibitors are now approved, their impact on Gamma Knife radiosurgery (GKRS) outcomes remains unexplored. We assessed the safety and efficacy of KRAS G12C inhibitors with GKRS compared with conventional systemic therapies. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Radiosurgery

Share to Treatment Outcome

Source

Identifiers

PMID: 42098425
DOI: 10.1007/s11060-026-05547-x

Genes

KRAS
ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.PMID 42098425Read ↗

Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Semantic proximity Read ↗

KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

Advances in the treatment of KRASG12C mutant non–small cell lung cancerSemantic proximity Read ↗

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case SeriesSemantic proximity Read ↗

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.Semantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.